Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-79635322 |
Synonyms | |
Therapy Description |
JNJ-79635322 is a trispecific antibody that targets TNFRSF17 (BCMA) and GPRC5D on tumor cells, and CD3 on T-cells, which potentially induces cytotoxicity against tumor cells (Blood (2023) 142 (Supplement 1): 456). |